• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

从人红细胞膜分离出的一种抑制性蛋白对人补体C3转化酶扩增的调节作用。

Regulation of the amplification C3 convertase of human complement by an inhibitory protein isolated from human erythrocyte membrane.

作者信息

Fearon D T

出版信息

Proc Natl Acad Sci U S A. 1979 Nov;76(11):5867-71. doi: 10.1073/pnas.76.11.5867.

DOI:10.1073/pnas.76.11.5867
PMID:293688
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC411753/
Abstract

An activity that is inhibitory to the properdin-stabilized amplification C3 convertase (C3b,Bb,P) was solubilized from human erythrocyte (E(hu)) membranes by Nonidet P-40 and purified to homogeneity. The inhibitory membrane glycoprotein had an apparent M(r) of 1-1.2x10(6) on gel filtration in the presence of Nonidet P-40. On sodium dodecyl sulfate/polyacrylamide gel electrophoresis it presented a single stained band with an apparent M(r) of 205,000, with or without prior reduction of disulfides. The inhibitory protein of the E(hu) membrane produced a dose-related, first-order decay of C3b,Bb,P function on sheep erythrocytes (E(s)) and released (125)I-labeled Bb from these sites, indicating a mechanism of inhibition by decay-dissociation of the amplification C3 convertase. The 50% inhibitory dose of the E(hu) membrane protein was not altered by removal of sialic acid from the E(s) bearing C3b,Bb,P sites. E(hu) membrane protein also serves as a cofactor for C3b inactivator-induced cleavage of the alpha polypeptide chain of C3b. Thus, the inhibitory membrane protein can abrogate the activity of amplification convertase sites that have formed and also can prevent generation of such sites by augmenting irreversible inactivation of C3b.Discrimination between cells by the alternative complement pathway occurs after initial deposition of C3b and is related to the modulation by surface constituents of the capacity of bound C3b to function as a subunit of the amplification C3 convertase. The existence in the E(hu) membrane of a protein that can impair the functions of membrane-bound C3b and C3b,Bb,P could represent a molecular basis for preventing inappropriate self-recognition.

摘要

一种对备解素稳定的补体C3转化酶(C3b,Bb,P)具有抑制作用的活性物质,通过Nonidet P - 40从人红细胞(E(hu))膜中溶解出来,并纯化至同质。在存在Nonidet P - 40的情况下,通过凝胶过滤法测得该抑制性膜糖蛋白的表观分子量为1 - 1.2×10⁶。在十二烷基硫酸钠/聚丙烯酰胺凝胶电泳中,无论是否预先还原二硫键,它都呈现出一条表观分子量为205,000的单一染色带。E(hu)膜的抑制性蛋白对绵羊红细胞(E(s))上的C3b,Bb,P功能产生剂量相关的一级衰减,并从这些位点释放出¹²⁵I标记的Bb,这表明其抑制机制是通过扩增C3转化酶的衰变解离。从带有C3b,Bb,P位点的E(s)上去除唾液酸后,E(hu)膜蛋白的50%抑制剂量并未改变。E(hu)膜蛋白还可作为C3b灭活剂诱导C3bα多肽链裂解的辅因子。因此,这种抑制性膜蛋白既能消除已形成的扩增转化酶位点的活性,又能通过增强C3b的不可逆失活来阻止此类位点的产生。补体替代途径对细胞的识别是在C3b初始沉积之后发生的,并且与表面成分对结合的C3b作为扩增C3转化酶亚基功能的调节能力有关。E(hu)膜中存在一种能够损害膜结合C3b和C3b,Bb,P功能的蛋白质,这可能是防止不适当自我识别的分子基础。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bbe6/411753/b67264d06ace/pnas00011-0462-a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bbe6/411753/b67264d06ace/pnas00011-0462-a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bbe6/411753/b67264d06ace/pnas00011-0462-a.jpg

相似文献

1
Regulation of the amplification C3 convertase of human complement by an inhibitory protein isolated from human erythrocyte membrane.从人红细胞膜分离出的一种抑制性蛋白对人补体C3转化酶扩增的调节作用。
Proc Natl Acad Sci U S A. 1979 Nov;76(11):5867-71. doi: 10.1073/pnas.76.11.5867.
2
Regulation by membrane sialic acid of beta1H-dependent decay-dissociation of amplification C3 convertase of the alternative complement pathway.膜唾液酸对替代补体途径中C3转化酶β1H依赖性衰变解离的调节作用。
Proc Natl Acad Sci U S A. 1978 Apr;75(4):1971-5. doi: 10.1073/pnas.75.4.1971.
3
Inhibition of complement activation on the surface of cells after incorporation of decay-accelerating factor (DAF) into their membranes.衰变加速因子(DAF)整合到细胞膜后对细胞表面补体激活的抑制作用。
J Exp Med. 1984 Nov 1;160(5):1558-78. doi: 10.1084/jem.160.5.1558.
4
Heparin prevents formation of the human C3 amplification convertase by inhibiting the binding site for B on C3b.肝素通过抑制B在C3b上的结合位点来阻止人C3转化酶的形成。
Mol Immunol. 1983 Dec;20(12):1401-4. doi: 10.1016/0161-5890(83)90172-4.
5
Residual hemolytic and proteolytic activity expressed by Bb after decay-dissociation of C3b,Bb.C3b、Bb衰变解离后Bb所表达的残余溶血和蛋白水解活性。
J Immunol. 1984 Mar;132(3):1425-9.
6
A circulating inhibitor of fluid-phase amplification. C3 convertase formation in systemic lupus erythematosus.液相放大的循环抑制剂。系统性红斑狼疮中C3转化酶的形成。
J Clin Invest. 1985 Jun;75(6):1786-95. doi: 10.1172/JCI111891.
7
Modulation of the formation of the amplification convertase of complement, C3b, Bb, by native and commercial heparin.天然肝素和商业肝素对补体C3b、Bb放大转化酶形成的调节作用。
J Exp Med. 1978 Feb 1;147(2):409-21. doi: 10.1084/jem.147.2.409.
8
The mechanism of action of decay-accelerating factor (DAF). DAF inhibits the assembly of C3 convertases by dissociating C2a and Bb.衰变加速因子(DAF)的作用机制。DAF通过解离C2a和Bb来抑制C3转化酶的组装。
J Exp Med. 1987 Nov 1;166(5):1221-8. doi: 10.1084/jem.166.5.1221.
9
Activation of the alternative complement pathway with rabbit erythrocytes by circumvention of the regulatory action of endogenous control proteins.通过规避内源性控制蛋白的调节作用,利用兔红细胞激活替代补体途径。
J Exp Med. 1977 Jul 1;146(1):22-33. doi: 10.1084/jem.146.1.22.
10
Complement C3 convertase: cell surface restriction of beta1H control and generation of restriction on neuraminidase-treated cells.补体C3转化酶:β1H调控的细胞表面限制及神经氨酸酶处理细胞上限制的产生
Proc Natl Acad Sci U S A. 1978 May;75(5):2416-20. doi: 10.1073/pnas.75.5.2416.

引用本文的文献

1
Gene expression analysis revealed downregulation of complement receptor 1 in clonal B cells in cold agglutinin disease.基因表达分析显示,冷凝集素病克隆性B细胞中补体受体1表达下调。
Clin Exp Immunol. 2024 Mar 12;216(1):45-54. doi: 10.1093/cei/uxad135.
2
The Molecular Mechanisms of Complement Receptor 1-It Is Complicated.补体受体 1 的分子机制——错综复杂。
Biomolecules. 2023 Oct 13;13(10):1522. doi: 10.3390/biom13101522.
3
Guardians of Immunity: Advances in Primary Immunodeficiency Disorders and Management.免疫守护者:原发性免疫缺陷疾病及其管理的进展

本文引用的文献

1
Protein measurement with the Folin phenol reagent.使用福林酚试剂进行蛋白质测定。
J Biol Chem. 1951 Nov;193(1):265-75.
2
The thiobarbituric acid assay of sialic acids.唾液酸的硫代巴比妥酸测定法。
J Biol Chem. 1959 Aug;234(8):1971-5.
3
Chemical coupling of peptides and proteins to polysaccharides by means of cyanogen halides.通过卤化氰将肽和蛋白质与多糖进行化学偶联。
Cureus. 2023 Sep 7;15(9):e44865. doi: 10.7759/cureus.44865. eCollection 2023 Sep.
4
Protein therapeutics and their lessons: Expect the unexpected when inhibiting the multi-protein cascade of the complement system.蛋白类药物及其启示:在抑制补体系统的多蛋白级联反应时,要预料到意料之外的情况。
Immunol Rev. 2023 Jan;313(1):376-401. doi: 10.1111/imr.13164. Epub 2022 Nov 18.
5
Recent Progress in Red Blood Cells-Derived Particles as Novel Bioinspired Drug Delivery Systems: Challenges and Strategies for Clinical Translation.红细胞衍生颗粒作为新型仿生药物递送系统的研究进展:临床转化面临的挑战与策略
Front Chem. 2022 Apr 27;10:905256. doi: 10.3389/fchem.2022.905256. eCollection 2022.
6
Aspects of the Complement System in New Era of Xenotransplantation.补体系统在新时代异种移植中的作用
Front Immunol. 2022 Apr 14;13:860165. doi: 10.3389/fimmu.2022.860165. eCollection 2022.
7
Complement System: An Immunotherapy Target in Colorectal Cancer.补体系统:结直肠癌的免疫治疗靶点。
Front Immunol. 2022 Jan 31;13:810993. doi: 10.3389/fimmu.2022.810993. eCollection 2022.
8
Acquired decrease of the C3b/C4b receptor (CR1, CD35) and increased C4d deposits on erythrocytes from ICU COVID-19 patients.从 ICU COVID-19 患者的红细胞上获得的 C3b/C4b 受体 (CR1、CD35) 减少和 C4d 沉积增加。
Immunobiology. 2021 May;226(3):152093. doi: 10.1016/j.imbio.2021.152093. Epub 2021 May 9.
9
Complement in Tumourigenesis and the Response to Cancer Therapy.补体在肿瘤发生及癌症治疗反应中的作用
Cancers (Basel). 2021 Mar 10;13(6):1209. doi: 10.3390/cancers13061209.
10
Spatially conserved motifs in complement control protein domains determine functionality in regulators of complement activation-family proteins.结构域中空间保守的补体调控蛋白基序决定补体激活调控因子家族蛋白的功能。
Commun Biol. 2019 Aug 5;2:290. doi: 10.1038/s42003-019-0529-9. eCollection 2019.
Nature. 1967 Jun 24;214(5095):1302-4. doi: 10.1038/2141302a0.
4
Methods for the separation, purification and measurement of nine components of hemolytic complement in guinea-pig serum.豚鼠血清中溶血补体九种成分的分离、纯化及测定方法
Immunochemistry. 1966 Mar;3(2):111-35. doi: 10.1016/0019-2791(66)90292-8.
5
The reliability of molecular weight determinations by dodecyl sulfate-polyacrylamide gel electrophoresis.通过十二烷基硫酸钠-聚丙烯酰胺凝胶电泳测定分子量的可靠性。
J Biol Chem. 1969 Aug 25;244(16):4406-12.
6
Extraction of complement inhibitory factors from the erythrocytes of non-human species.从非人类物种的红细胞中提取补体抑制因子。
J Immunol. 1973 Sep;111(3):946-51.
7
Alternate complement pathway: factors involved in cobra venom factor (CoVF) activation of the third component of complement (C3).替代补体途径:参与眼镜蛇毒因子(CoVF)激活补体第三成分(C3)的相关因子。
J Immunol. 1973 Jan;110(1):128-38.
8
Electrophoretic analysis of the major polypeptides of the human erythrocyte membrane.人红细胞膜主要多肽的电泳分析。
Biochemistry. 1971 Jun 22;10(13):2606-17. doi: 10.1021/bi00789a030.
9
Lactoperoxidase coupled to polyacrylamide for radio-iodination of proteins to high specific activity.与聚丙烯酰胺偶联的乳过氧化物酶用于蛋白质的放射性碘化以获得高比活性。
Immunochemistry. 1974 Apr;11(4):203-6. doi: 10.1016/0019-2791(74)90329-2.
10
Formation of a hemolytically active cellular intermediate by the interaction between properdin factors B and D and the activated third component of complement.备解素因子B和D与补体激活的第三成分相互作用形成具有溶血活性的细胞中间体。
J Exp Med. 1973 Dec 1;138(6):1305-13. doi: 10.1084/jem.138.6.1305.